A phase 1/2a study is recruiting patients to evaluate emavusertib, an IRAK-4 inhibitor, monotherapy in adults with AML or high-risk MDS, which includes patients with R/R AML or high-risk MDS with U2AF1, SF3B1, or FLT3 mutations (NCT04278768) [157]. Here, U2AF1 is linked to myelodysplastic syndrome.